Geode Capital Management’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-1,301,165
| Closed | -$455K | – | 4120 |
|
|
2016
Q3 | $455K | Buy |
1,301,165
+42,540
| +3% | +$14.9K | ﹤0.01% | 3286 |
|
|
2016
Q2 | $586K | Buy |
1,258,625
+30,910
| +3% | +$14.4K | ﹤0.01% | 3155 |
|
|
2016
Q1 | $1.67K | Buy |
1,227,715
+123,736
| +11% | +$168 | ﹤0.01% | 2575 |
|
|
2015
Q4 | $1.62M | Buy |
1,103,979
+9,387
| +0.9% | +$13.8K | ﹤0.01% | 2599 |
|
|
2015
Q3 | $1.73M | Buy |
1,094,592
+8,459
| +0.8% | +$13.4K | ﹤0.01% | 2539 |
|
|
2015
Q2 | $1.85M | Buy |
1,086,133
+240,987
| +29% | +$410K | ﹤0.01% | 2550 |
|
|
2015
Q1 | $1.17M | Buy |
845,146
+140,567
| +20% | +$195K | ﹤0.01% | 2781 |
|
|
2014
Q4 | $1.06M | Sell |
704,579
-886
| -0.1% | -$1.34K | ﹤0.01% | 2799 |
|
|
2014
Q3 | $1.45M | Buy |
705,465
+7,510
| +1% | +$15.5K | ﹤0.01% | 2561 |
|
|
2014
Q2 | $2.13M | Buy |
697,955
+115,687
| +20% | +$354K | ﹤0.01% | 2337 |
|
|
2014
Q1 | $1.46M | Buy |
582,268
+92,973
| +19% | +$232K | ﹤0.01% | 2540 |
|
|
2013
Q4 | $2.43M | Buy |
489,295
+55,574
| +13% | +$276K | ﹤0.01% | 2177 |
|
|
2013
Q3 | $985K | Buy |
433,721
+100,200
| +30% | +$228K | ﹤0.01% | 2603 |
|
|
2013
Q2 | $740K | Buy |
+333,521
| New | +$740K | ﹤0.01% | 2639 |
|
Geode Capital Management's RXII Position: Q4 2016 in Review
Geode Capital Management sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 1,301,165 shares — an estimated $455K sold.
Geode Capital Management first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $2.43M in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Geode Capital Management reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Geode Capital Management sold 1,301,165 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $455K.
- Geode Capital Management first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- Geode Capital Management's GALENA BIOPHARMA INC COM position peaked at $2.43M in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Geode Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.